Sign in

    Anthea Li

    Senior Associate in Biotechnology Equity Research at Jefferies

    Anthea Li is a Senior Associate in Biotechnology Equity Research at Jefferies, specializing in equity analysis of biotechnology companies with a focus on the investment banking sector. She covers a range of firms within the biotech industry, delivering data-driven insights that support investor decision-making. With approximately three years of experience in equity research—including previous associate roles—Anthea joined Jefferies as a Senior Associate and is based in New York; she holds a Bachelor of Arts from the University of California, Berkeley. As a licensed professional (CRD# 7613274), she is registered with FINRA and upholds regulatory standards for research analysts.

    Anthea Li's questions to VERU (VERU) leadership

    Anthea Li's questions to VERU (VERU) leadership • Q3 2025

    Question

    Anthea Li of Jefferies inquired about Veru's new modified-release formulation of Inovasarm, asking about its potential for fixed-dose combinations with oral GLP-1s and any updates on ex-U.S. partnering discussions.

    Answer

    Chairman, President & CEO, Mitchell Steiner, confirmed that a fixed-dose combination with oral GLP-1s is feasible and could extend patent life. He stated that Veru is actively engaged in partnership discussions with three categories of companies: established GLP-1 market leaders, large pharmaceutical companies looking to enter the weight-loss space, and companies developing their own GLP-1s that need a differentiator. The primary goal of these discussions is to secure non-dilutive funding for future studies.

    Ask Fintool Equity Research AI

    Anthea Li's questions to VERU (VERU) leadership • Q1 2025

    Question

    Anthea Li, on for Dennis Ding of Jefferies, questioned the potential for a fixed-dose combination of oral enobosarm with oral GLP-1s, the comparative hsCRP reduction of sabizabulin versus Colchicine, and the feasibility of a Phase II study given the company's cash position.

    Answer

    Chairman, CEO, and President Dr. Mitchell Steiner confirmed a fixed-dose oral combination is possible and attractive. Regarding sabizabulin, he stated that while its mechanism is similar to Colchicine, it has a superior safety profile without the drug-drug interactions with statins, making it a "safety play." He expects similar or better hsCRP reduction. Dr. Steiner also affirmed the company has sufficient cash to operate through the end of the calendar year, covering key data readouts.

    Ask Fintool Equity Research AI

    Anthea Li's questions to Crinetics Pharmaceuticals (CRNX) leadership

    Anthea Li's questions to Crinetics Pharmaceuticals (CRNX) leadership • Q1 2025

    Question

    Anthea Li, on for Dennis Ding, requested an update on enrollment and follow-up in the long-term extension study for CAH and asked what would constitute a critical mass of data for a public update.

    Answer

    Dr. R. Struthers, CEO, confirmed that enrollment in the open-label extension (OLE) is ongoing but declined to provide specific numbers or timing for a data release. He emphasized the OLE's value in gathering real-world evidence and stated that data would be presented at a scientific meeting once a sufficient dataset is available.

    Ask Fintool Equity Research AI